Type 2 diabetes cases in US, Europe and Japan could rise to 61.2M by 2035

Hypertension will lead diagnosed comorbidities across the seven major markets.

Type 2 diabetes (T2D) cases across the seven major markets (7MM) are projected to increase to 61.2 million in 2035 from 54.5 million in 2025, with hypertension emerging as the most prevalent diagnosed comorbidity, according to GlobalData.

The 7MM comprises the US, Japan and 5 European countries–France, Germany, Italy, Spain and the UK.

GlobalData’s Type 2 Diabetes (T2D): Epidemiology Forecast to 2035 report said diagnosed cases are expected to grow at an annual growth rate of 1.2% over the period.

The US is expected to have the highest number of diagnosed cases across the 7MM, at just under 29.6 million in 2035.

Japan and the 5 European countries are estimated to have approximately 8.6 million and 22.9 million diagnosed cases in 2035, respectively, the firm said.

GlobalData epidemiologists said higher BMI is a key risk factor for developing T2D, with Germany and the US recording higher prevalence rates that could be linked to lifestyle factors.

“The high prevalence rates of T2D in Germany and the US may be explained by both markets having high rates of obesity and ageing populations,” said Judith Visser, Epidemiologist at GlobalData.

BMI tends to be higher in Western Europe and the US, where processed-food diets, sedentary lifestyles, and desk-based work are prevalent. Ageing populations also contribute to the increasing prevalence of T2D.

The firm found that hypertension accounted for most diagnosed prevalent cases with a diagnosed comorbidity, with the highest proportion of comorbid hypertension observed in Germany.

“Hypertension is a common comorbidity worldwide, as it is associated with a higher BMI, lower physical activity levels, and a poor diet. The high comorbidity burden in patients with T2D shows the importance of proper disease management,” Visser added.